<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02175186</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV 2014-05</org_study_id>
    <nct_id>NCT02175186</nct_id>
  </id_info>
  <brief_title>Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention</brief_title>
  <acronym>DAPTALBIS</acronym>
  <official_title>Protective Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Young-Hak Kim, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate effectiveness of ALBIS on Gastroduodenal Mucosal
      Injury in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary
      Intervention.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of gastric ulcer</measure>
    <time_frame>12weeks</time_frame>
    <description>defined as a mucosal break of at least 5 mm in diameter(measured by gastrointestinal endoscopy) with depth, at 12weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of gastritis</measure>
    <time_frame>12weeks</time_frame>
    <description>defined as Modified Lanza Score(MLS) grade 2~4(measured by gastrointestinal endoscopy)at 12weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Endoscopic improvement rate of hemorrhage</measure>
    <time_frame>12weeks</time_frame>
    <description>defined as Modified Lanza Score(MLS) grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Endoscopic improvement rate of subjective symptom</measure>
    <time_frame>12weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of antacid used during study period</measure>
    <time_frame>12weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Gastritis</condition>
  <condition>Gastroduodenal Ulcer</condition>
  <arm_group>
    <arm_group_label>ALBIS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Albis Tab 2 tab twice a day 12weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo Tab 2 tab twice a day 12weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALBIS</intervention_name>
    <arm_group_label>ALBIS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20 and 80 years

          -  Patients undergoing percutaneous coronary intervention and need to take dual
             antiplatelet therapy continuously at least 12weeks

          -  Modified Lanza Score grade 0-1 measured by upper gastrointestinal endoscopy

          -  mild gastrointestinal symptom

          -  Creatinen in blood ≤ 3mg/dl

          -  BUN ≤ 50mg/dl

          -  Birilubin ≤ 3mg/dl

          -  AST and ALT ≤ 80U/L

        Exclusion Criteria:

          -  Pregnant or breast feeding

          -  History of Stomach or esophagus surgery

          -  Peptic ulcer or reflux esophagitis

          -  Zollinger-Ellison syndrome or primary esophageal motility disorders

          -  Malignant tumor

          -  Bleeding tendency or coagulopathy

          -  Contraindication of ALBIS

          -  Long term use of aspirin or P2Y12 receptor antagonist within 1month

          -  Patients who tool medicine such as PPI, APA,H2blocker, Muscarine receptor antagonist,
             anti-gastic agent, antacid, anticaogulant, Bisphosphonate agents, Cytotoxic drug,
             NSAID, adrenal cortex hormone agents (topical treatment is allowed)

          -  Terminal patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Hak Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young-Hak Kim, MD</last_name>
    <email>mdyhkim@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eun-Young Lee, CRC</last_name>
    <email>cvcrc21@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-Gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Hak Kim, MD, PhD</last_name>
      <phone>82-2-3010-3955</phone>
      <email>mdyhkim@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Young-Hak Kim, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2014</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Young-Hak Kim, MD, PhD</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <keyword>Gastritis</keyword>
  <keyword>Gastroduodenal Ulcer</keyword>
  <keyword>Percutaneous Coronary Revascularization</keyword>
  <keyword>Dual Antiplatelet Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Peptic Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

